FY2025 · ended Dec 31, 2025 · Revenue $490.73M, +110.5% YoY · Filed Feb 19, 2026
Travere Therapeutics, Inc. (TVTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $490.7 million and a net loss of $25.5 million. As of Sep 30, 2026 it held $471.8 million in cash and investments and $12.6 million in total debt.
Revenue (TTM)
$651.03M
+49.4% vs year-ago TTM
Net income (TTM)
$-121.51M
-37.2% vs year-ago TTM
Operating cash flow (TTM)
$176.59M
+401.3% vs year-ago TTM
Free cash flow
$-280.69M
-50.5% vs prior year
EPS (TTM)
$-1.31
-29.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
92.24M
+3.9% vs prior year
Net cash
$459.17M
as of Sep 30, 2026
Operating margin
-20.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438533
- Former names
- Retrophin, Inc. (until Nov 13, 2020); Desert Gateway, Inc. (until Feb 19, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$180.1M |
| Diluted EPS | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 |
| Operating cash flow | $37.8M | -$237.5M | -$280.0M | -$186.3M | -$14.8M |
| Free cash flow | — | — | -$280.7M | -$186.5M | -$19.9M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M |
| Stockholders' equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M |
| Cash and investments | $322.8M | $370.7M | $566.9M | $450.2M | $552.9M |
| Total debt | $17.0M | $22.6M | $27.5M | $31.9M | $35.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 21, 2026 | Sep 21, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 9, 2026 | Jul 6, 2026 |
All 1000 Travere Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.